BioMarin Pharmaceutical Inc.（BMRN）财务数据BMRNBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. (BMRN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is POMBILITI OPFOLDA, accounting for 103.1% of total sales, equivalent to $1.02B. Other significant revenue streams include Voxzogo and Vimizim. Understanding this composition is critical for investors evaluating how BMRN navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, BioMarin Pharmaceutical Inc. maintains a gross margin of 72.08%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 16.91%, while the net margin is 4.52%. These profitability ratios, combined with a Return on Equity (ROE) of 1.18%, provide a clear picture of how effectively BMRN converts its operational activities into shareholder value.

In the context of the broader market, BMRN competes directly with industry leaders such as ELAN and TECH. With a market capitalization of $10.58B, it holds a significant position in the sector. When comparing efficiency, BMRN's gross margin of 72.08% stands against ELAN's 48.17% and TECH's 66.02%. Such benchmarking helps identify whether BioMarin Pharmaceutical Inc. is trading at a premium or discount relative to its financial performance.

The company has shown strong revenue growth, with Q2 2026 revenue at $989.71 million, and a gross margin of 72.08%. Despite some recent net income fluctuations, the overall trend remains positive with a net income of $44.76 million in Q2 2026.